Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Apr 2001

Ewesuedo R B, Iyer L, Das S, Koenig A, Mani S, Vogelzang N J, Schilsky R L, Brenckman W, Ratain M J

Abstract excerpt

PURPOSE: TAS-103 is an inhibitor of both topoisomerase I and II enzymes with broad antitumor activity. It is metabolized to TAS-103-glucuronide (TAS-103-G) predominantly by uridine diphosphate glucuronosyltransferase isoform 1A1 (UGT1A1). We conducted a phase I study to determine the maximum-tole...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoquinolines
Share to Antineoplastic Agents
Share to Glucuronosyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indenes

Share to Maximum Tolerated Dose

Share to Pharmacogenetics

Share to Salvage Therapy

Share to Topoisomerase II Inhibitors

Source

Identifiers

PMID: 11283142
DOI: 10.1200/JCO.2001.19.7.2084

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-11283142-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.PMID 11283142Read ↗

Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.Semantic proximity Read ↗

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.Semantic proximity Read ↗

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.Semantic proximity Read ↗

Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.Semantic proximity Read ↗

Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.Semantic proximity Read ↗

Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours.Semantic proximity Read ↗

DNA Topoisomerases as Targets for the Anticancer Drug TAS-103: Primary Cellular Target and DNA Cleavage EnhancementSemantic proximity Read ↗

A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.Semantic proximity Read ↗

Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.Semantic proximity Read ↗

A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.Semantic proximity Read ↗

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of SurvivinSemantic proximity Read ↗

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.